Gauging adequacy of cardiovascular disease treatment: importance of estimating glomerular filtration rate and time-varying albuminuria

Journal of the American Society of Hypertension

Volumn 3, Issue 4, 2009, Pages 277-285

  Weir, Matthew R ^a   Townsend, Raymond ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cardiovascular risk; chronic kidney disease; end stage renal disease; renin angiotensin system

Indexed keywords

CHOLESTEROL; GLUCOSE;

AGE; ALBUMINURIA; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; FAMILY HISTORY; GENDER; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

EID: 67650708198     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2008.05.008     Document Type: Review

References (43)

1. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., and Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
2. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States (2004), National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland
3. Levey A.S., Beto J.A., Coronado B.E., Eknoyan G., Foley R.N., Kasiske B.L., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32 (1998) 853-906
4. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
5. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2002) S1-S266
6. Coresh J., Astor B.C., Greene T., Eknoyan G., and Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
7. Sarnak M.J., and Levey A.S. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 35 (2000) S117-S131
8. Sarnak M.J., Levey A.S., Schoolwerth A.C., Coresh J., Culleton B., Hamm L.L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108 (2003) 2154-2169
9. Shemesh O., Golbetz H., Kriss J.P., and Myers B.D. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 28 (1985) 830-838
10. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
11. Weir M.R. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2 (2007) 581-590
12. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 (2001) 421-426
13. Arnlov J., Evans J.C., Meigs J.B., Wang T.J., Fox C.S., Levy D., et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112 (2005) 969-975
14. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE Substudy. Lancet 355 (2000) 253-259
15. Pedrinelli R., Dell'Omo G., Penno G., and Mariani M. Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease. Vasc Med 6 (2001) 257-264
16. Gosling P. Microalbuminuria: a marker of systemic disease. Br J Hosp Med 54 (1995) 285-290
17. Clausen P., Jensen J.S., Jensen G., Borch-Johnsen K., and Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 103 (2001) 1869-1874
18. Paisley K.E., Beaman M., Tooke J.E., Mohamed-Ali V., Lowe G.D., and Shore A.C. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int 63 (2003) 624-633
19. Stehouwer C.D., and Smulders Y.M. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 17 (2006) 2106-2111
20. Walker III M., Harrison-Bernard L.M., Cook A.K., and Navar L.G. Dynamic interaction between myogenic and TGF mechanisms in afferent arteriolar blood flow autoregulation. Am J Physiol Renal Physiol 279 (2000) F858-F865
21. Sorensen C.M., Leyssac P.P., Skott O., and Holstein-Rathlou N.H. Role of the renin-angiotensin system in regulation and autoregulation of renal blood flow. Am J Physiol Regul Integr Comp Physiol 279 (2000) R1017-R1024
22. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
23. Anderson S., Meyer T.W., Rennke H.G., and Brenner B.M. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76 (1985) 612-619
24. Maschio G., Alberti D., Janin G., Locatelli F., Mann J.F., Motolese M., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334 (1996) 939-945
25. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
26. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
27. Brenner B.M., Cooper M.E., deZeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
28. Viberti G., Mogensen C.E., Groop L.C., and Pauls J.F. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 271 (1994) 275-279
29. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
30. Wachtell K., Ibsen H., Olsen M.H., Borch-Johnsen K., Lindholm L.H., Mogensen C.E., et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Ann Intern Med 139 (2003) 901-906
31. Ibsen H., Olsen M.H., Wachtell K., Borch-Johnsen K., Lindholm L.H., Mogensen C.E., et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45 (2005) 198-202
32. Jafar T.H., Schmid C.H., Landa M., Giatras I., Toto R., Remuzzi G., et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135 (2001) 73-87
33. deZeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65 (2004) 2309-2320
34. deZeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 (2004) 921-927
35. Eijkelkamp W.B., Zhang Z., Remuzzi G., Parving H.H., Cooper M.E., Keane W.F., et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18 (2007) 1540-1546
36. Atkins R.C., Briganti E.M., Lewis J.B., Hunsicker L.G., Braden G., Champion de Crespigny P.J., et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45 (2005) 281-287
37. Williams B., Lacy P.S., Thom S.M., et al., The CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee, and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 113 (2006) 1213-1225
38. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
39. Hollenberg N.K., Parving H.H., Viberti G., Remuzzi G., et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 25 (2007) 1921-1926
40. Heeg J.E., de Jong P.E., van der Hem G.K., and deZeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36 (1989) 272-279
41. Vogt L., Waanders F., Boomsma F., deZeeuw D., and Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 19 (2008) 999-1007
42. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
43. Remuzzi G., and Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339 (1998) 1448-1456